PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Rimegepant - Migraine (acute)

PAD Profile : Rimegepant - Migraine (acute)

Keywords :
Acute migraine, migraine treatment, calcitonin gene-related peptide inhibitors, CGRP antagonists
Brand Names Include :
Vydura

Traffic Light Status

Status 1 of 1.

Status :
Green
Formulations :
  • Oral lyophilisates
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

Additional Documents

No additional documents returned.

Committee Recommendations

Date
Committee Name
Narrative
07 February 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) approves rimegepant for the acute treatment of Migraine with or without aura in adults in line with NICE TA919.

A GREEN traffic light status has been agreed.

Treatment with rimegepant for acute migraine is recommended by NICE, only if for previous migraines:

  • at least 2 triptans were tried and these did not work well enough or
  • triptans were contraindicated or not tolerated, and nonsteroidal anti-inflammatory drugs (NSAIDs) and paracetamol were tried but did not work well enough.

Patients receiving 8 or more tablets per month should be considered for preventative treatment.

Associated BNF Codes

04. Central Nervous System
04.07.04. Antimigraine drugs
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More